(Q35591053)

9 August 2017

1 reference

title

Hypertension in people with Type 2 diabetes: knowledge-based diabetes-specific guidelines (English)

1 reference

9 August 2017

0 references

Working Party of the International Diabetes Federation (European Region)

series ordinal

1

1 reference

9 August 2017

publication date

1 December 2003

1 reference

9 August 2017

1 reference

9 August 2017

volume

20

1 reference

9 August 2017

issue

12

1 reference

9 August 2017

page(s)

972-987

1 reference

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Diabetes mellitus and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Detection and treatment of hypertension in patients with non-insulin-dependent diabetes mellitus: does the 'rule of halves' apply to a diabetic population?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Blood pressure, stroke, and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Guidelines for management of hypertension: report of the third working party of the British Hypertension Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Updated New Zealand cardiovascular disease risk-benefit prediction guide

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Lifestyle and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

The problem of ventricular dysrhythmias and sudden death mortality in heart failure: the impact of current therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Treatment of hypertension in patients with type 2 diabetes: a review of the recent evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Higher blood pressure in adults with less education. Some explanations from INTERSALT

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Blood pressure control, microalbuminuria and cardiovascular risk in Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Beta-blockers for the treatment of hypertension in patients with diabetes: exploring the contraindication myth

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Angiotensin II receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Limitations of the difference between clinic and daytime blood pressure as a surrogate measure of the ‘white-coat’ effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

Risk Factors for Stroke in Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2003.01021.X

10.1046/J.1464-5491.2003.01021.X

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference